Cagrilintide is a long-acting amylin analogue that produces substantial weight loss in clinical trials. This article examines a narrower research question — whether that weight loss could translate into lower type 2 diabetes incidence in high-risk populations — and where the current evidence stops short.

Why high-risk cohorts progress to type 2 diabetes

Type 2 diabetes emerges from a slow interplay of two defects: peripheral insulin resistance and a progressive decline in pancreatic beta-cell function. As tissues respond less efficiently to insulin, the beta cells compensate by secreting more, and over time that compensatory capacity erodes until glucose regulation fails.¹ Populations described as “high-risk” — individuals with prediabetes, central obesity, or a strong family history — sit on the steep part of that trajectory, where relatively small metabolic shifts can move a person across the diagnostic threshold.

Excess visceral adiposity is one of the most consistent drivers of insulin resistance, which is why body-weight reduction has long been studied as a way to slow or interrupt progression. The landmark Diabetes Prevention Program (DPP) demonstrated that a lifestyle programme targeting roughly 7% weight loss reduced the incidence of type 2 diabetes by 58% over about three years in adults with impaired glucose tolerance, outperforming metformin.² That trial established the central premise this article interrogates: if weight loss lowers diabetes incidence, could a pharmacological agent that produces larger weight loss than lifestyle alone extend the same benefit? Cagrilintide is one of the candidates researchers raise in that discussion.

What cagrilintide is and how amylin signalling works

Amylin (islet amyloid polypeptide) is co-secreted with insulin from pancreatic beta cells in response to nutrient intake. Its physiological role is to act as a satiation signal and a brake on postprandial glucose excursions. Studies characterising amylin describe three complementary actions: it delays gastric emptying, suppresses inappropriate glucagon secretion after meals, and engages amylin receptors in the hindbrain to promote satiation and limit energy intake.³ Reviews of amylin biology trace how these effects were mapped over roughly three decades and why the hormone became a target for metabolic drug development.⁴

Native amylin is short-lived and aggregation-prone, which limits its direct use. Cagrilintide was engineered as a long-acting amylin analogue suitable for once-weekly subcutaneous administration.⁵ Mechanistic reviews note that it engages amylin receptors across both homeostatic and hedonic circuits, so appetite suppression is thought to arise from more than one pathway.⁶ Because amylin and GLP-1 act through distinct but convergent routes to reduce food intake, cagrilintide has also been developed alongside the GLP-1 receptor agonist semaglutide as the fixed combination CagriSema, on the rationale that the two mechanisms are additive.⁶

Weight loss as the proposed lever on diabetes risk

The prevention hypothesis rests on a chain of reasoning rather than a single trial. Link one: modest, sustained weight loss reduces diabetes incidence in high-risk adults, as the DPP quantified.² Link two: cagrilintide produces weight loss well beyond what lifestyle programmes typically achieve. In a phase 2 dose-finding trial in adults with overweight or obesity and without diabetes, once-weekly cagrilintide monotherapy produced mean weight reductions of roughly 6–11% at 26 weeks across doses, exceeding placebo and, at the top dose, exceeding once-daily liraglutide 3.0 mg.⁵

If a research model accepts both links, cagrilintide-induced reduction in visceral fat would be expected to improve insulin sensitivity and thereby lower the probability of crossing into diabetes. That is a coherent mechanistic argument, and it is the reason the compound appears in prevention discussions. It is not, however, the same as a trial that randomised high-risk, non-diabetic participants and counted how many developed diabetes. The distinction matters and is revisited below.

What the clinical trials actually measured

The cagrilintide programme has been studied mainly in two populations: adults with obesity (with or without established type 2 diabetes) and adults who already have type 2 diabetes. The endpoints have been body weight, glycated haemoglobin (HbA1c), fasting plasma glucose, and continuous glucose monitoring parameters — measures of weight and glycaemic control, not measures of new-onset diabetes.

In a 32-week phase 2 trial in adults with type 2 diabetes, CagriSema lowered HbA1c by about 2.2 percentage points and reduced body weight by roughly 15.6%; the HbA1c change was greater than cagrilintide alone but not statistically greater than semaglutide alone, while weight loss was greater than either monotherapy.⁷ The larger phase 3a REDEFINE programme then extended these findings. In REDEFINE 1, in adults with overweight or obesity but without diabetes, CagriSema produced an estimated mean weight change of −20.4% at 68 weeks versus −3.0% with placebo.⁸ In REDEFINE 2, in adults with overweight or obesity and type 2 diabetes, CagriSema produced a −13.7% weight change versus −3.4% with placebo, and 73.5% of the CagriSema group reached an HbA1c of 6.5% or lower, compared with 15.9% on placebo.⁹ A regional phase 3a trial in Japan and Taiwan (REDEFINE 5) reported −18.4% with CagriSema versus −11.9% with semaglutide alone.¹⁰

A recurring observation across these datasets is that gastrointestinal events — nausea, vomiting, diarrhoea, constipation — were the most common adverse events, generally transient and mild-to-moderate, and more frequent than placebo.⁸⁹ Tolerability is therefore part of any honest reading of the data, not a footnote.

The prevention evidence gap

Here is where the research question meets its limit. Every trial summarised above enrolled participants who were already living with obesity, established type 2 diabetes, or both. None was designed as a diabetes-prevention study — that is, none randomised a high-risk, non-diabetic (prediabetic) cohort and then measured how many progressed to a diabetes diagnosis over time. The REDEFINE 1 population was non-diabetic, but its endpoints were weight change and weight-loss thresholds, not incident diabetes.⁸

So the accurate statement is narrow: cagrilintide reliably produces the kind of weight loss that, in other interventions, has been associated with lower diabetes incidence,² and it improves glycaemic measures in people who already have diabetes.⁷⁹ Whether it lowers the rate of new diabetes diagnoses in high-risk individuals has not been directly tested and cannot be claimed from the current literature. Reviews of the wider incretin and amylin landscape frame these agents as promising and rapidly evolving, while noting that long-term outcome data are still accumulating.¹¹ Any prevention framing should be read as a testable hypothesis, not a settled result.

How cagrilintide compares with other strategies

Placing cagrilintide next to the alternatives clarifies both its interest and its unverified status for the specific prevention question.

Lifestyle modification

Structured diet-and-exercise programmes are the only intervention with direct, randomised evidence for reducing diabetes incidence in high-risk adults, as the DPP showed.² Their well-documented limitation is durability: sustained adherence and long-term weight maintenance are difficult, which is what motivates pharmacological research in the first place.

GLP-1 receptor agonists

GLP-1 receptor agonists such as semaglutide produce strong glycaemic and weight effects but show heterogeneous individual response and commonly cause gastrointestinal side effects.¹² Cagrilintide acts through the distinct amylin pathway, which is the biological rationale for combining the two rather than treating them as interchangeable.⁶

Dual and triple agonists

The comparator field now includes the GLP-1/GIP dual agonist tirzepatide and triple GLP-1/GIP/glucagon agonists such as retatrutide, with reported weight-loss ranges reaching into the low-to-mid 20% territory at higher doses.¹³ Cagrilintide-based combinations sit within this competitive weight-loss range, but head-to-head prevention comparisons do not exist.

Bariatric surgery

Metabolic surgery yields the largest and most durable weight loss and strong metabolic improvement, but it carries procedural risk, cost, and access constraints that make it unsuitable for broad preventive use.¹³ Cagrilintide is sometimes positioned as a pharmacological bridge between lifestyle change and surgery — a framing that describes its weight-loss magnitude, not a demonstrated prevention outcome.

All Qovigen peptides are sold for laboratory and research use only (RUO). Not for human or veterinary use, diagnosis, or treatment.